New hope for tough cancers: experimental drug targets specific genetic flaw
NCT ID NCT04439110
Summary
This study is testing whether a drug called ado-trastuzumab emtansine can shrink or stop the growth of advanced cancers that have a specific genetic change called HER2 amplification. The trial is for patients with various hard-to-treat cancers (like lymphoma and solid tumors), but specifically excludes breast and stomach cancers. The drug is designed to deliver chemotherapy directly to cancer cells that have the HER2 marker.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.